These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 37742166)

  • 1. Magnitude of Viral Load Suppression and Associated Factors among HIV-positive Patients Receiving Antiretroviral Therapy.
    Acharya P; Neupane AP; Sigdel B; Ghimire L; Pant MR; Budhathoki A; Poudyal A
    J Nepal Health Res Counc; 2023 Sep; 21(1):159-164. PubMed ID: 37742166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV virological non-suppression and factors associated with non-suppression among adolescents and adults on antiretroviral therapy in northern Ethiopia: a retrospective study.
    Desta AA; Woldearegay TW; Futwi N; Gebrehiwot GT; Gebru GG; Berhe AA; Godefay H
    BMC Infect Dis; 2020 Jan; 20(1):4. PubMed ID: 31898535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
    Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
    Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.
    Opoku S; Sakyi SA; Ayisi-Boateng NK; Enimil AK; Senu E; Ansah RO; Aning BD; Ojuang DA; Wekesa DN; Ahmed FO; Okeke CB; Sarfo AD
    AIDS Res Ther; 2022 May; 19(1):21. PubMed ID: 35614510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
    Martin DA; Luz PM; Lake JE; Clark JL; Veloso VG; Moreira RI; Cardoso SW; Klausner JD; Grinsztejn B
    BMC Infect Dis; 2014 Jun; 14():322. PubMed ID: 24919778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti.
    Jean Louis F; Buteau J; François K; Hulland E; Domerçant JW; Yang C; Boncy J; Burris R; Pelletier V; Wagar N; Deyde V; Lowrance DW; Charles M
    PLoS One; 2018; 13(1):e0192077. PubMed ID: 29381736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with recent unsuppressed viral load in HIV-1-infected patients in care on first-line antiretroviral therapy in South Africa.
    Joseph Davey D; Abrahams Z; Feinberg M; Prins M; Serrao C; Medeossi B; Darkoh E
    Int J STD AIDS; 2018 May; 29(6):603-610. PubMed ID: 29334886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards the UNAIDS 95-95-95 targets among pregnant women in South Africa: Results from the 2017 and 2019 national Antenatal HIV Sentinel Surveys.
    Woldesenbet S; Cheyip M; Lombard C; Manda S; Ayalew K; Kufa T; Puren A
    PLoS One; 2022; 17(7):e0271564. PubMed ID: 35862306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics.
    Parczewski M; Siwak E; Leszczyszyn-Pynka M; Cielniak I; Burkacka E; Pulik P; Witor A; Muller K; Zasik E; Grzeszczuk A; Jankowska M; Lemańska M; Olczak A; Grąbczewska E; Szymczak A; Gąsiorowski J; Szetela B; Bociąga-Jasik M; Skwara P; Witak-Jędra M; Jabłonowska E; Wójcik-Cichy K; Kamerys J; Janczarek M; Krankowska D; Mikuła T; Kozieł K; Bielec D; Stempkowska J; Kocbach A; Błudzin W; Horban A
    J Int AIDS Soc; 2017 Jul; 20(1):21847. PubMed ID: 28715160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
    Meireles MV; Pascom ARP; Duarte EC; McFarland W
    AIDS; 2019 Aug; 33(10):1663-1668. PubMed ID: 31082860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cross sectional study assessing factors associated with retention and non-viral suppression among HIV positive FSWs receiving antiretroviral therapy from primary health care facilities in Kampala, Uganda.
    Atuhaire L; Shumba CS; Mapahla L; Nyasulu PS
    BMC Infect Dis; 2022 Jul; 22(1):642. PubMed ID: 35883042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
    Sutton SS; Magagnoli J; Hardin JW
    Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy.
    Kerschberger B; Boulle AM; Kranzer K; Hilderbrand K; Schomaker M; Coetzee D; Goemaere E; Van Cutsem G
    J Int AIDS Soc; 2015; 18(1):20092. PubMed ID: 26403636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virologic failure in HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional study.
    Natukunda J; Kirabira P; Ong KIC; Shibanuma A; Jimba M
    Trop Med Health; 2019; 47():8. PubMed ID: 30679930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnitude of Viral Load Suppression and Associated Factors among Clients on Antiretroviral Therapy in Public Hospitals of Hawassa City Administration, Ethiopia.
    Anito AA; Lenjebo TL; Woticha E; Solomon F
    HIV AIDS (Auckl); 2022; 14():529-538. PubMed ID: 36425750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
    Ongubo DM; Lim R; Tweya H; Stanley CC; Tembo P; Broadhurst R; Gugsa S; Ngongondo M; Speight C; Heller T; Phiri S; Hosseinipour MC
    BMC Infect Dis; 2017 Jul; 17(1):461. PubMed ID: 28673254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.